Suppr超能文献

以革兰氏阴性杆菌中的β-内酰胺耐药性为重点的抗菌药物耐药性

Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli.

作者信息

Pitout J D, Sanders C C, Sanders W E

机构信息

Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA.

出版信息

Am J Med. 1997 Jul;103(1):51-9. doi: 10.1016/s0002-9343(97)00044-2.

Abstract

beta-Lactam antibiotics are the most frequently prescribed antibiotics worldwide. Therefore, it is not surprising that resistance to this very important class of agents poses an increasingly complex and perplexing problem for physicians. Among the variety of mechanisms that can provide resistance to beta-lactam antibiotics in gram-negative bacilli, the production of beta-lactamase is by far the single most important factor. With the introduction of newer beta-lactam agents observed changes in beta-lactamases include the increased prevalence of older enzymes, the appearance of new enzymes, and alteration in the level of expression of the enzymes. These changes have been responsible for resistance to newer cephalosporins, monobactams, carbapenems, and beta-lactamase inhibitor/beta-lactam drug combinations. Resistance to beta-lactam antibiotics has also emerged through alterations in the targets of the drugs, the penicillin-binding proteins, and through alterations in outer membrane permeability of the organisms to the drugs. With some beta-lactam agents, multiple mechanisms must be acquired before clinically relevant levels of resistance are attained. This is especially true for carbapenems and fourth generation cephalosporins. Nevertheless, resistance to beta-lactam antibiotics is on the rise among clinical isolates of gram-negative bacilli, and only through more judicious use of these agents can their usefulness for treatment and prevention of infections be preserved.

摘要

β-内酰胺类抗生素是全球处方量最高的抗生素。因此,对这类非常重要的药物产生耐药性给医生带来了日益复杂和棘手的问题也就不足为奇了。在革兰氏阴性杆菌中,能对β-内酰胺类抗生素产生耐药性的多种机制中,β-内酰胺酶的产生是迄今为止最重要的单一因素。随着新型β-内酰胺类药物的出现,β-内酰胺酶的变化包括旧有酶的流行率增加、新酶的出现以及酶表达水平的改变。这些变化导致了对新型头孢菌素、单环β-内酰胺类、碳青霉烯类以及β-内酰胺酶抑制剂/β-内酰胺类药物组合产生耐药性。对β-内酰胺类抗生素的耐药性还通过药物靶点(青霉素结合蛋白)的改变以及生物体对药物外膜通透性的改变而出现。对于某些β-内酰胺类药物,在达到临床相关耐药水平之前必须获得多种机制。碳青霉烯类和第四代头孢菌素尤其如此。然而,革兰氏阴性杆菌临床分离株对β-内酰胺类抗生素的耐药性正在上升,只有更明智地使用这些药物,才能保持它们在治疗和预防感染方面的效用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验